Our firm
Vie Ventures is positioned at the intersection of life sciences venture capital and disease-focused philanthropy, serving as a bridge between the two to catalyze the development of innovative therapeutics.
We seek to generate attractive financial returns aligned with mission impact for our stakeholders by investing in therapeutic companies creating next generation therapies and cures. Our initial focus is in autoimmune disease and other disorders of the immune system, which is an area of significant unmet needs experiencing a period of rapid innovation within biotechnology.
To that end, we participate in the equity syndicate alongside other leading venture capital investors and strategic partners. The expertise and experience of our network of strategic collaborators from disease-focused ecosystems enables us to serve as a value-added investment partner for our portfolio companies and our fellow investors.
As a result, Vie Ventures is uniquely positioned to align for-profit venture capital with disease-focused philanthropy to achieve our mission of delivering life-changing therapies and cures for patients.
